Enanta Pharmaceuticals (ENTA)
(Real Time Quote from BATS)
$12.14 USD
-0.44 (-3.50%)
Updated Aug 12, 2024 09:56 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Enanta Pharmaceuticals, Inc. [ENTA]
Reports for Purchase
Showing records 61 - 80 ( 164 total )
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Next Week We''ll Kick Off Our Management Talk Series
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Upcoming Webinars to Discuss Near-Term Catalysts with Our Covered Companies
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Undervalued Pipeline of Potential Blockbusters. Resume Buy, $104 PT.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare- Three Must Dial-In Calls Next Week:
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Three Must Dial-In Calls Next Week: NASH, Omega-3s, and COVID-19 - MS
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q20 - Protected Despite COVID with Multiple Key Trials Slated for 2020
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
COVID-19''s Viral Drug Discovery - Development Is Fated to Be a Tiger
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare- Yas'' Weekly Recap of Our Key Notes and 20 Doc Calls Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Dial in to Part 2 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Dial in to Part 1 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Dial in to Parts 1-2 of Our COVID-19 Drug Developer Series on Apr. 1 - Apr. 2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y